gETL NPs bear CD47, a molecule which prevents phagocytosis through interaction with SIRPα on the surface of macrophages.[39, 40, 41, 42] We speculated that treatment with gETL NPs would occupy SIRPα, thereby disengaging the interaction of SIRPα on macrophages with CD47 on tumor cells and thus promoting macrophage‐mediated tumor cell phagocytosis. Here, SIRPA is linked to neoplasm.